Cell therapy in patients with COVID-19

Phase 1

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20190717044241N2
• Lead Sponsor: Barakat Pharmaceutical Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Persistent hypoxemia despite receiving less than 93% Saturation oxygen
Respiratory failure requires a Ventilator
Chest has multilobar infiltrates
Shock
Organ failure

Exclusion Criteria

Patient dissatisfaction
Pregnant patient
Age less than 17 years
Patient with known active malignancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical response. Timepoint: 28 days-From the time of cell injection until the 28th day. Method of measurement: clinical observation by Infectious Diseases Specialist.;O2 saturation. Timepoint: 0,3,6days.Since the injection of the cell. Method of measurement: ventilator.;Inflammation cytokines. Il-6 & Il-10. Timepoint: 0,3,6,14 days-Since the injection of the cell. Method of measurement: Assay by the Elisa.